Annexon Lands Up to $200M Credit Facility from Oxford Finance, Drawing $50M at Close
ANNX has more than doubled off its 52-week low of $2.03.
Summary
Annexon secured a strategic credit facility of up to $200 million from Oxford Finance, drawing an initial $50 million. The non-dilutive capital supports advancement of its neuroinflammatory disease programs toward registration.
Key Events · Financing and Capital Events · ANNX
-
Up to $200M Credit Facility
Annexon entered a Loan and Security Agreement with Oxford Finance LLC for term loans of up to $200 million, with $50 million funded at closing.
-
Non-Dilutive Capital
The facility provides capital without issuing equity, preserving shareholder value while funding operations and potential commercialization.
-
Milestone-Based Tranches
An additional $100 million becomes available upon achieving clinical/regulatory milestones for vonaprument and tanruprubart; the final $50 million is subject to lender approval.
-
Financial Terms
Loans bear interest at the greater of 1-Month CME Term SOFR + 4.6% or 7.60%, with interest-only payments until at least September 2029 and maturity in 2031/2032.
Analysis · ANNX · Life Sciences
Annexon entered a loan agreement that provides up to $200 million in non-dilutive capital, with $50 million drawn immediately. The facility is tied to clinical and regulatory milestones for its lead programs, vonaprument and tanruprubart. This strengthens the balance sheet and extends cash runway without immediate shareholder dilution, though it adds debt and asset encumbrances. The deal signals lender confidence in the company's pipeline ahead of potential commercialization.
At the time of this filing, ANNX was trading at $5.37 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $863.5M. The 52-week trading range was $2.03 to $7.18. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.